We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
The emergence of COVID-19 variants such as delta and omicron have sent scientists scrambling to determine whether existing vaccinations and boosters are still effective against new strains of SARS-Cov-2.
Swedish researchers are gearing up to seek permission from Bangladeshi authorities to hold clinical trials of a nasal COVID-19 vaccine in the country, reported the Dhaka Tribune.
Scientists at Washington University School of Medicine in St. Louis have developed a vaccine that targets the SARS-CoV-2 virus, can be given in one dose via the nose and is effective in preventing infection in mice susceptible to the novel coronavirus.